10-K: Rapport Therapeutics Navigates Clinical Holds and Advances Epilepsy Program in 2024

Rapport Therapeutics focuses on precision medicines for neurological and psychiatric disorders, advancing its lead candidate for epilepsy while addressing regulatory hurdles in other indications.

Summary

• Rapport Therapeutics, a clinical-stage biotechnology company, is focused on developing precision medicines for neurological and psychiatric disorders.
• The company's lead product candidate, RAP-219, targets focal epilepsy and is currently in a Phase 2a proof-of-concept trial, with topline results expected in the third quarter of 2025.
• RAP-219 is also being evaluated for bipolar disorder, with a Phase 2a trial planned for the third quarter of 2025 and topline results expected in the first half of 2027.
• In the fourth quarter of 2024, the FDA placed a clinical hold on the IND for a Phase 2a trial of RAP-219 for diabetic peripheral neuropathic pain (DPNP), requesting additional protocol information.
• The company is deferring further investment in RAP-199 and focusing resources on RAP-219's three proof-of-concept clinical trials.
• Rapport Therapeutics has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs targeting chronic pain and hearing disorders.
• The company reported a net loss of $78.3 million for the year ended December 31, 2024, and believes its existing cash will fund operations through the end of 2026.
• As of December 31, 2024, the company had 69 full-time employees, with 50 in research and development.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is progress in the epilepsy program, the clinical hold on the DPNP trial and the company's ongoing losses temper the overall outlook.

Positives

• RAP-219 is in Phase 2a development for refractory focal epilepsy, with topline results expected in Q3 2025.
• The company plans to initiate a Phase 2a trial of RAP-219 for bipolar mania in Q3 2025.
• Rapport has two discovery-stage nAChR programs targeting chronic pain and hearing disorders.
• The company believes it can address the FDA's concerns regarding the clinical hold on the RAP-219 DPNP trial.
• The company's existing cash, cash equivalents and short-term investments will enable it to fund its operating expenses and capital expenditure requirements through the end of 2026.

Negatives

• The FDA placed a clinical hold on the IND for a Phase 2a trial of RAP-219 for DPNP.
• The company reported a net loss of $78.3 million for the year ended December 31, 2024.
• The company is deferring further investment in RAP-199 and focusing resources on RAP-219's three proof-of-concept clinical trials.

Risks

• The company's business is highly dependent on the success of its product candidates, particularly RAP-219 for focal epilepsy.
• The regulatory approval processes of the FDA, EMA, MHRA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable.
• The company will require additional funding in order to finance operations.
• The company is dependent on a third party having accurately generated, collected, interpreted and reported data from certain preclinical studies and clinical trials that were previously conducted for its product candidates.
• The company depends on in-licensed intellectual property.
• The company may be subject to claims that it wrongfully hired an employee from a competitor or that its employees have misappropriated intellectual property, including trade secrets of their former employers.

Future Outlook

The company believes its existing cash will fund operations through the end of 2026 and plans to advance RAP-219 clinical development and expand its pipeline.

Management Comments

• Management believes in their ability to advance the clinical development of RAP-219 for DPNP.
• Management expects to report topline results from the Phase 2a proof-of-concept trial in refractory focal epilepsy in the third quarter of 2025.

Industry Context

The company operates in the competitive biotechnology and pharmaceutical industries, facing competition from various companies developing therapies for neurological and psychiatric disorders.

Comparison to Industry Standards

• The document mentions perampanel (FYCOMPA) as an approved ASM that directly antagonizes all AMPARs throughout the brain, but notes that RAP-219's actions are restricted to specific neurons that express TARP 8, potentially leading to a differentiated tolerability profile.
• The document mentions XCOPRI (cenobamate), XEN1101, BHV-7000, PRAX-628, darigabet, ES-481, SPN-817 and ADX71149 as competitors in the focal epilepsy space.
• The document mentions lithium, Lamictal, selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors as competitors in the bipolar disorder space.
• The document mentions duloxetine, venlafaxine, amitriptyline, gabapentinoids and opioids as competitors in the peripheral neuropathic pain space.
• The document mentions VX-548, LX9211 and BHV-2100 as competitors in the peripheral neuropathic pain space.

Related Party Transactions

• The company incurred costs to Janssen Pharmaceutical NV for the use of lab space.
• The company incurred costs to Third Rock Ventures LLC for management consulting and other various start-up support activities.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in clinical trials will impact shareholder value.
• Employees: The company's ability to attract and retain qualified personnel is crucial for its success.
• Patients: The development of new treatments for neurological and psychiatric disorders could improve patient outcomes.
• Suppliers: The company's reliance on third-party manufacturers creates a dependency on their performance.

Next Steps

• Report topline results from Phase 2a proof-of-concept trial in refractory focal epilepsy in the third quarter of 2025.
• Initiate Phase 2a proof-of-concept trial in bipolar mania in the third quarter of 2025.
• Provide an update on the anticipated timing of the Phase 2a trial initiation for DPNP once available.
• Advance development of RAP-enabled nAChR programs.
• Pursue strategic partnerships opportunistically.

Key Dates